{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T06:03:06Z","timestamp":1763186586034,"version":"3.45.0"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukoreduced red blood cells (LR\u2010RBCs) prepared from whole blood (WB) with the Reveos\u2122 Automated Blood Processing System (Reveos System) are required to meet US Food and Drug Administration (FDA) criteria for RBC component in vitro quality and in vivo 24\u2010h RBC recovery after 42\u2010day storage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design and Methods<\/jats:title>\n                    <jats:p>\n                      For the in vitro study, 65 Reveos\u2010derived LR\u2010RBC units were stored for 42\u2009days in citrate phosphate dextrose (CPD)\/Additive Solution Formula 5 (AS\u20105). Units were evaluated for post\u2010filtration residual white blood cell (rWBC) content, post\u2010filtration RBC recovery, and percent hemolysis at end of storage. In vivo 24\u2010h recovery of 42\u2010day stored autologous Reveos\u2010derived LR\u2010RBCs was determined in 26 healthy participants with standard single (\n                      <jats:sup>51<\/jats:sup>\n                      Cr) and dual\u2010label (\n                      <jats:sup>51<\/jats:sup>\n                      Cr\/\n                      <jats:sup>99m<\/jats:sup>\n                      Tc) methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For all evaluable units processed in the in vitro study, post\u2010filtration rWBC content was &lt;5\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      \/RBC unit (65\/65), post\u2010filtration RBC recovery was \u226585% (63\/63), and hemolysis was \u22641% after 42\u2010day storage in AS\u20105 (65\/65)\u2009=\u2009100% for all parameters, one\u2010sided 95% lower confidence limit (LCL)\u2009\u2265\u200995%. Single label in vivo recoveries were\u2009\u226575% in 23 of 26 infusions (95% LCL\u2009=\u200973%), with an average of 83% (standard deviation [SD]\u2009=\u20099%). When corrected by actual red cell mass, dual label in vivo recoveries were\u2009\u226575% in 24 out of 26 infusions (95% LCL\u2009=\u200978%) with a mean of 90% (SD\u2009=\u20099%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Reveos System met FDA's criteria for RBC component in vitro quality and in vivo 24\u2010h recovery after 42\u2010day storage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.18427","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:16:29Z","timestamp":1761070589000},"page":"2144-2152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro and in vivo evaluation of leukoreduced red blood cells after automated separation of whole blood"],"prefix":"10.1111","volume":"65","author":[{"given":"Rebecca L.","family":"Sedjo","sequence":"first","affiliation":[{"name":"Clinical Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina K.","family":"Aga","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa J.","family":"Flaumenhaft","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-1674","authenticated-orcid":false,"given":"Moritz","family":"Stolla","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest Research Institute  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1715-0748","authenticated-orcid":false,"given":"Larry J.","family":"Dumont","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute  Denver Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Marschner","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute  Denver Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Sutor","sequence":"additional","affiliation":[{"name":"Carter BloodCare  Bedford Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-7699","authenticated-orcid":false,"given":"Frances","family":"Compton","sequence":"additional","affiliation":[{"name":"Carter BloodCare  Bedford Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawnagay","family":"Nestheide","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center, University of Cincinnati  Cincinnati Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeta","family":"Rugg","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center, University of Cincinnati  Cincinnati Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marley","family":"Shipps","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nero","family":"Evero","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Lawrence","family":"Bailey","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest Research Institute  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daire","family":"Byrne","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest Research Institute  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Gloor","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Leite","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute  Denver Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Cancelas","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center, University of Cincinnati  Cincinnati Ohio USA"},{"name":"Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice J.","family":"Chen","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Terumo Blood and Cell Technologies  Lakewood Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005361"},{"issue":"4","key":"e_1_2_10_3_1","first-page":"S8","article-title":"Continued stabilization of blood collections and transfusions in the United States: findings from the 2021 National Blood Collection and Utilization Survey","volume":"63","author":"Free RJ","year":"2023","journal-title":"Transfusion"},{"issue":"2","key":"e_1_2_10_4_1","first-page":"87A","article-title":"Whole\u2010blood\u2010derived platelets prepared from automated processing are similar to platelets from manual processing at the end of storage","volume":"62","author":"Aga G","year":"2022","journal-title":"Transfusion"},{"issue":"2","key":"e_1_2_10_5_1","first-page":"174A","article-title":"In vitro quality parameters of platelet pools are similar when pooled 1\u2010 or 2\u2010days after automated whole blood processing","volume":"62","author":"Aga G","year":"2022","journal-title":"Transfusion"},{"issue":"2","key":"e_1_2_10_6_1","first-page":"179A","article-title":"Plasma, red blood cells, and platelet units from whole blood collected in a new blood bag set and processed on an automated system meet in vitro acceptance criteria","volume":"62","author":"Aga G","year":"2022","journal-title":"Transfusion"},{"issue":"5","key":"e_1_2_10_7_1","first-page":"126A","article-title":"Interim platelet units prepared from automated WB processing meet in vitro acceptance criteria and are less activated than manually prepared PRP platelets","volume":"63","author":"Aga G","year":"2023","journal-title":"Transfusion"},{"volume-title":"Technical Manual: Methods and Appendices, 20th Edition, Appendix 1","year":"2020","author":"AABB","key":"e_1_2_10_8_1"},{"volume-title":"Blood Donor History Questionnaires","author":"AABB","key":"e_1_2_10_9_1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1980.tb07189.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24284173339.x"},{"issue":"8","key":"e_1_2_10_12_1","first-page":"793","article-title":"Recommended methods for measurement of red\u2010cell and plasma volume","volume":"21","author":"International Committee for Standardization in Haematology","year":"1980","journal-title":"J Nucl Med"},{"issue":"2","key":"e_1_2_10_13_1","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler SB","year":"1962","journal-title":"Surgery"},{"volume-title":"Presentation: FDA Evaluation of Red Cell Products","year":"2016","author":"Vostal J","key":"e_1_2_10_14_1"},{"volume-title":"Guidance for industry: pre\u2010storage leukocyte reduction of whole blood and blood components intended for transfusion","year":"2021","key":"e_1_2_10_15_1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12233"},{"volume-title":"Common terminology criteria for adverse events (CTCAE) v5.0","year":"2021","author":"National Cancer Institute","key":"e_1_2_10_17_1"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12051"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12010"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12836"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30316-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103195"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000516696"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1975.tb02756.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:58:26Z","timestamp":1763186306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.18427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/trf.18427"],"URL":"https:\/\/doi.org\/10.1111\/trf.18427","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"2024-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}